Join Professor John Camm and Professor John Eikelboom in their discussion of the association between bleeding occurrence and new cancer diagnosis among patients with atherosclerosis receiving antithrombotic therapy.
The COMPASS trial, involving over 27,000 patients, investigated whether rivaroxaban alone or rivaroxaban in combination with aspirin, would be more effective than aspirin alone for secondary cardiovascular prevention in patients with stable atherosclerotic vascular disease. Additionally, the association between bleeding occurrence and new cancer diagnosis in these patients was evaluated, which is what this 30-minute journal club explores and discusses.
View abstract Access full paper
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
This educational activity is designed for hospitalists, oncologists, haematologists, interventional cardiologists, internists/physicians, surgeons, and any other healthcare professional with an interest or role in the management of patients on anticoagulation.
After completing this educational activity, participants should be able to:
- Describe the association between gastrointestinal and genitourinary bleeding, and new cancer diagnosis, among patients with atherosclerosis receiving antithrombotic therapy
- Recall the clinical implications of gastrointestinal and genitourinary bleeding in patients treated with antithrombotic therapy
Prof John Camm
- Advisor for: Boehringer Ingelheim, Daiichi Sankyo
- Consultant (retained) for: Boehringer Ingelheim
- Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
- Consulting fees and/or honoraria received from: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis
- Grants and/or in-kind support received from: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis
Staff and reviewer disclosures
PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This independent educational activity is supported by funding from Portola Pharmaceuticals Inc. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.